The company said Canada is the first G7 country to grant market authorization for semaglutide injection.
In Canada, Dr Reddy’s semaglutide injection is indicated for the once a week treatment of adults with type 2 diabetes mellitus to improve glycemic control in combination with diet and exercise, it said.
The same is supplied as a sterile solution for subcutaneous injection in a pre-filled pen, available in 2 mg/pen and 4mg/pen strengths, each delivering semaglutide at a concentration of 1.34 mg/ml.The 2 mg/pen is designed to deliver 0.25 mg or 0.5 mg doses while the 4 mg/pen delivers 1 mg doses per injection, the company said.
“The Canada launch builds on the momentum of our recent launch in India under the brand name Obeda. As GLP-1 therapies continue to be a key focus area for us, we are actively working to expand access across multiple global markets,” Erez Israeli, CEO, Dr Reddy’s, said.
Shares of Dr Reddy’s Laboratories Ltd. ended the previous session 3% up at ₹1,343.2 apiece. The stock has risen 10% in the past month.
Also Read: Tata Motors acquires 18% stake in Freight Tiger for ₹96 crore; total holding to reach 64%
